Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Domperidone→

Domperidone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
57808-66-9
Molecular formula
C22H24ClN5O2
Molecular weight
425.9 g/mol
Drug class
Peripheral dopamine D2-receptor antagonistantiemetic and prokinetic
Mechanism of action
Blocks peripheral dopamine D2 receptors in the chemoreceptor trigger zone and gastrointestinal tract, producing antiemetic effects and increasing upper gastrointestinal motility.
Indications / reported uses
  • Relief of symptoms of nausea and vomiting; use, dose and duration are restricted by product information and jurisdiction-specific cardiac safety precautions

Sources: UK SmPC — Domperidone 1 mg/ml oral suspension (updated 14 Nov 2025) · Health Canada Drug Product Database

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Peripheral dopamine D2-receptor antagonist; antiemetic and prokinetic

Mechanism of action

Blocks peripheral dopamine D2 receptors in the chemoreceptor trigger zone and gastrointestinal tract, producing antiemetic effects and increasing upper gastrointestinal motility.

General use cases

  • Relief of symptoms of nausea and vomiting; use, dose and duration are restricted by product information and jurisdiction-specific cardiac safety precautions

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Domperidone Environmental Risk Assessment (ERA) (the Domperidone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.